Inspira Technologies Announces That The ART’s Device ‘brain’ IS To Acquire An Algorithm Enhanced Digital Platform

Inspira Technologies OXY B.H.N. Ltd ("Inspira Technologies" or the "Company") (NASDAQ:IINN) (NASDAQ:IINNW), a specialty medical device company engaged in the research, development, manufacturing, and

Inspira Technologies OXY B.H.N. Ltd (“Inspira Technologies” or the “Company”) (NASDAQ:IINN) (NASDAQ:IINNW), a specialty medical device company engaged in the research, development, manufacturing, and marketing of proprietary respiratory support technologies,  announced today that the the ART’s device “brain” is to acquire an algorithm enhanced digital platform,  for which the Company has contracted GlobalLogic, a Hitachi Group Company (“GlobalLogic”), a world leader in digital product engineering.

The “brain” of the ART device is an algorithm-enhanced control platform. A unique feature of the ART’s “brain” is the algorithm-based “hemo-protective patient’s flow rate”– an algorithm that is designed to manage the early rebalancing of the patient’s oxygen saturation levels. In addition, it includes a digital algorithm enhanced platform designed to activate and control proprietary technologies and data collected from advanced sensors that measure oxygen saturation, blood temperature, haemoglobin, and haematocrit as well as pressure and flow of blood. 

Dagi Ben-Noon, Inspira’s CEO, stated: “With concern over the rising morbidity associated with the COVID-19 pandemic, Inspira Technologies is progressing towards the production phase of the ART device’s “brain”, an algorithm enhanced platform.  The ART is designed to provide oxygenation of blood and removal of carbon dioxide from the blood. With GlobalLogic, we are pleased to integrate an advanced digital algorithm into our innovative control platform and to provide a more advanced digital experience for the medical personnel who will use it.

Chet Kolley, Group Vice President, Health Care and Life Sciences, GlobalLogic, stated: “We have all witnessed the wide-reaching impact of COVID-19 and the stress it has created on healthcare resources.  It’s very gratifying to see industry leaders stepping forward to solve these critical problems. We are thrilled to work with Inspira Technologies on this game-changing technology and looking forward to the potential positive impact it will have on human lives.”

Inspira Technologies selected GlobalLogic for its vast experience in working with regulated industries such as medical device and pharmaceutical companies. GlobalLogic works with many of the world’s leading medical technology, healthcare, and life sciences organizations to create world-class digital patient experiences, get products to market faster, uncover and capture new revenue streams, and transform healthcare through technology and innovation.

Total
0
Shares
Related Posts